- Conditions
- Chronic Renal Insufficiency
- Interventions
- Recombinant Human Growth Hormone
- Drug
- Lead sponsor
- Weill Medical College of Cornell University
- Other
- Eligibility
- 6 Months to 21 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1997 – 2003
- U.S. locations
- 1
- States / cities
- New York, New York
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 193–216
of 1,880
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Chronic Kidney Disease, Glomerulopathy
- Interventions
- Not listed
- Lead sponsor
- University of Michigan
- Other
- Eligibility
- Not listed
- Enrollment
- 1,800 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009 – 2030
- U.S. locations
- 5
- States / cities
- Ann Arbor, Michigan • Detroit, Michigan • Charlotte, North Carolina + 1 more
- Conditions
- End-stage Renal Disease
- Interventions
- Ultrafiltration
- Procedure
- Lead sponsor
- Renal Research Institute
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2011
- U.S. locations
- 3
- States / cities
- New York, New York
- Conditions
- Atherosclerotic Cardiovascular Disease (ASCVD), Chronic Kidney Disease (CKD)
- Interventions
- Retatrutide, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 45 Years and older
- Enrollment
- 10,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 204
- States / cities
- Alabaster, Alabama • Birmingham, Alabama • Daphne, Alabama + 159 more
- Conditions
- ESRD
- Interventions
- Immune Tolerance
- Drug
- Lead sponsor
- Everett Meyer
- Other
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2025
- U.S. locations
- 2
- States / cities
- Stanford, California • Madison, Wisconsin
- Conditions
- Secondary Hyperparathyroidism, Renal Failure, Chronic Renal Insufficiency
- Interventions
- Hectorol (doxercalciferol capsules), 0.5mcg
- Drug
- Lead sponsor
- Genzyme, a Sanofi Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2007
- U.S. locations
- 17
- States / cities
- Phoenix, Arizona • Alhambra, California • Riverside, California + 14 more
- Conditions
- Uremic Pruritus
- Interventions
- CR845 0.5 mcg/kg, Placebo
- Drug
- Lead sponsor
- Cara Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 378 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 57
- States / cities
- Homewood, Alabama • Huntsville, Alabama • Bakersfield, California + 52 more
- Conditions
- IgA Nephropathy, CKD Associated With Type 1 Diabetes, Focal Segmental Glomerulosclerosis, Autosomal Dominant Polycystic Kidney
- Interventions
- Bardoxolone methyl capsules
- Drug
- Lead sponsor
- Biogen
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 103 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 30
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 27 more
- Conditions
- End-Stage Renal Disease, Type 2 Diabetes
- Interventions
- Dexcom Real-time G6 Continuous Glucose Monitoring System (CGM), POC Glucose Testing
- Device
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 53 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 2
- States / cities
- Atlanta, Georgia
- Conditions
- Anemia Associated With Chronic Kidney Disease
- Interventions
- Vadadustat, Darbepoetin alfa, Epoetin alfa
- Drug
- Lead sponsor
- Akebia Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 46 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2020
- U.S. locations
- 10
- States / cities
- Escondido, California • Denver, Colorado • Fort Lauderdale, Florida + 7 more
- Conditions
- CKD Stage 3, CKD Stage 4, Secondary Hyperparathyroidism, VDI
- Interventions
- CTAP101
- Drug
- Lead sponsor
- OPKO Health, Inc.
- Industry
- Eligibility
- 1 Month to 17 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 5
- States / cities
- Kansas City, Missouri • Columbus, Ohio • Philadelphia, Pennsylvania + 2 more
- Conditions
- End Stage Renal Disease, AV Fistula, Fistula, End Stage Kidney Disease
- Interventions
- Ellipsys Vascular Access Catheter
- Device
- Lead sponsor
- Medtronic Endovascular
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 103 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 5
- States / cities
- Tempe, Arizona • San Diego, California • Plano, Texas + 2 more
- Conditions
- End Stage Renal Disease, Arteriovenous Fistula, Arteriovenous Graft
- Interventions
- Arteriovenous Fistula (AVF), Arteriovenous Graft (AVG)
- Procedure
- Lead sponsor
- University of Pittsburgh
- Other
- Eligibility
- 65 Years and older
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania
- Conditions
- Hypertension (HTN)
- Interventions
- Combination Product: FDC of spironolactone and ER torsemide, Combination Product: Stabilized doses of loop diuretic and finerenone
- Drug
- Lead sponsor
- Sarfez Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Vienna, Virginia
- Conditions
- End-Stage Renal Disease
- Interventions
- Daclizumab, Methylprednisolone/prednisone, Mycophenolate mofetil, Sirolimus, Bactrim, Ganciclovir, Lipitor
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- Up to 21 Years
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2006
- U.S. locations
- 1
- States / cities
- Rockville, Maryland
- Conditions
- Chronic Hepatitis B
- Interventions
- TAF
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 124 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 4
- States / cities
- Los Angeles, California • San Jose, California • Detroit, Michigan + 1 more
- Conditions
- Kidney Failure, Chronic
- Interventions
- Tacrolimus (Arm B), Clotrimazole Troche, Tacrolimus (Arm A), Nystatin Suspension
- Drug
- Lead sponsor
- Weill Medical College of Cornell University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Non-diabetic Chronic Kidney Disease
- Interventions
- Empagliflozin, Placebo
- Drug
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 18 Years and older
- Enrollment
- 52 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- End Stage Kidney Disease, End Stage Renal Disease, Acute Kidney Injury
- Interventions
- Intermittent Renal Replacement Therapy using the Tablo Hemodialysis System, Intermittent Renal Replacement Therapy using Conventional Hemodialysis Systems
- Device
- Lead sponsor
- Outset Medical
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 458 participants
- Timeline
- 2021 – 2022
- U.S. locations
- 2
- States / cities
- Orlando, Florida • Fort Worth, Texas
- Conditions
- Thrombosis, Factor XI, Renal Impairment, ESRD (End-Stage Renal Disease)
- Interventions
- BMS-986177
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 1
- States / cities
- Orlando, Florida
- Conditions
- Chronic Kidney Disease (Stages 4 and 5), Health Related Quality of Life
- Interventions
- Electronic patient-reported outcome measure (ePROM) for symptom monitoring
- Behavioral
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2030
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- End Stage Renal Disease
- Interventions
- AAT-023 solution (Zuragen), Heparin
- Device · Drug
- Lead sponsor
- Ash Access Technology
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 415 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2006
- U.S. locations
- 22
- States / cities
- Bakersfield, California • Lynwood, California • Middlebury, Connecticut + 17 more
- Conditions
- Chronic Kidney Diseases
- Interventions
- Fruits and Vegetable increase
- Other
- Lead sponsor
- Nand Wadhwa
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 13 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2026
- U.S. locations
- 1
- States / cities
- Port Jefferson Station, New York
- Conditions
- Fabry Disease, Proteinuria
- Interventions
- enalapril and other angiotensin converting enzyme inhibitors; losartan and other angiotensin receptor blockers
- Drug
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 19 Years to 85 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2012
- U.S. locations
- 5
- States / cities
- Birmingham, Alabama • Atlanta, Georgia • Chicago, Illinois + 2 more